2 terminated, 2 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 2, Withdrawn 2 |
Follow EMA400: new trials by email Literature Review of EMA400 trials Research Report on EMA400
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN) EMA401, Placebo - Painful Diabetic Neuropathy | Phase 2 | Terminated | Novartis Pharmaceuticals | 142 | 2018-03-14 | 2021-10-08 |
| Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN) EMA401, Placebo - Post-herpetic Neuralgia | Phase 2 | Terminated | Novartis Pharmaceuticals | 130 | 2017-06-27 | 2021-10-08 |
| Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy EMA401 600mg, Placebo - Diabetic Neuropathies | Phase 2 | Withdrawn | Spinifex Pharmaceuticals Pty Ltd | 2015-06-01 | 2015-08-26 | |
| Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN EMA401 200 mg, EMA401 600 mg, Placebo - Neuralgia, Postherpetic | Phase 2 | Withdrawn | Spinifex Pharmaceuticals Pty Ltd | 2015-06-01 | 2015-08-26 |
Diabetic Neuropathies (2) · Neuralgia (2) · Neuralgia, Postherpetic (2)
Novartis Pharmaceuticals (2) · Spinifex Pharmaceuticals Pty Ltd (2)
Australia (2) · Austria (2) · Belgium (2) · Canada (2) · Denmark (2) · France (2) · Germany (2) · Hungary (2) · Norway (2) · Poland (2) · Portugal (2) · Slovakia (2) · Spain (2) · United Kingdom (2) · Bulgaria (1)
2016 (1)